Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 5Terminated 2Active not recruiting 2Recruiting 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Liver Neoplasms 1

Interventions

pembrolizumab 112Carboplatin 47Nivolumab 41Paclitaxel 34Cyclophosphamide 32Cisplatin 32Gemcitabine 30atezolizumab 28venetoclax 25Specimen Handling 24Pemetrexed 24Magnetic Resonance Spectroscopy 24fludarabine 22Docetaxel 22Biopsy 22Bevacizumab 22Azacitidine 22Radiotherapy 21Ipilimumab 21Radiosurgery 18Fluorouracil 18durvalumab 17Dexamethasone 17Cetuximab 17fludarabine phosphate 14Trastuzumab 14Leucovorin 14Radiation 13Injections 13Cytarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Docosahexaenoic Acids × 1 year × Clear all
NCT00422877 2025-10-16

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

American Regent, Inc.

Phase 2 Terminated
13 enrolled
Gastrointestinal

Liver Neoplasms

NCT00087776 2025-07-23

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

American Regent, Inc.

Phase 3 Terminated
393 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡